. 2022 Mar 8;11(4):e220028. doi: 10.1530/EC-22-0028
This work is licensed under a Table 1.
Anthropometric and laboratory characteristics of the study groups.
| Parameters | NC (n = 59) | PT (n = 19) | CPP (n = 67) | P |
|---|---|---|---|---|
| CA (years) | 7.61 ± 0.92 | 7.34 ± 1.04 | 7.55 ± 1.39 | 0.677 |
| BA (years) | - | 7 (7, 7.5) | 9 (7.5, 10)a | 0.000c |
| BA-CA (years) | - | −0.2 (−0.84, 0.61) | 1.1 (0.52, 1.84)a | 0.000c |
| Height (cm) | 123.20 ± 6.09 | 122.65 ± 6.80 | 129.78 ± 11.18ab | 0.000c |
| Weight (kg) | 22.4 (20.7, 25.0) | 23.9 (20.2, 26.4) | 27.1 (23.3, 32.1)ab | 0.000c |
| BMI (kg/m2) | 14.9 (14.26, 15.42) a | 15.75 (14.48, 16.48) | 15.87 (14.75, 17.19)b | 0.000c |
| Uterus volume (mL) | - | 1.50 (0.69, 2.87) | 2.72 (1.63, 4.73)a | 0.002c |
| Ovarian volume (m) | - | 1.83 (1.44, 2.48) | 2.24 (1.43, 4.11) | 0.155 |
| E2 (pmol/L) | 59.26 (23.75, 77.53)a | 92.16 (47.64, 104.92) | 108.30 (73.82, 158.63)b | 0.000c |
| B-LH (IU/L) | 0.11 (0.06, 0.16) | 0.11 (0.05, 0.17) | 1.00 (0.30, 2.14)ab | 0.000c |
| P-LH (IU/L) | - | 3.64 (2.75, 4.32) | 15.18 (9.13, 33.99)a | 0.000c |
| B-FSH (IU/L) | 1.72 (1.31, 2.16) | 2.10 (1.51, 2.60) | 3.73 (2.41, 5.71)ab | 0.000c |
| P-FSH (IU/L) | - | 13.34 (11.31, 15.68) | 17.69 (12.57, 23.47)a | 0.039c |
| P-LH/P-FSH | - | 0.27 (0.18, 0.34) | 1.11 (0.63, 1.87)a | 0.000c |
| IGF-1 (nmol/L) | - | 31.46 (24.32, 38.98) | 43.49 (32.53, 52.87)a | 0.002c |
| Insulin (pmol/L) | - | 8.14 ± 4.85 | 12.34 ± 6.21a | 0.034c |
| GLU (mmol/L) | - | 4.61 ± 0.33 | 4.46 ± 0.44 | 0.300 |
| HOMA-IR | - | 1.74 ± 0.98 | 2.53 ± 1.31 | 0.068 |
| Irisin (ng/ml) | 61.8 (38.9, 97.17)a | 100.28 (68.06, 170.63) | 159.23 (77.12, 289.46)b | 0.000c |
Values are expressed as mean ±standard deviation (s.d.) for normally distributed variables or expressed as median (interquartile ranges) for non-normally distributed variables. Statistical significance is represented as camong three groups P < 0.05, avs. PT group P < 0.05 and bvs NC group P < 0.05.
B-, base; BA, bone age; BA-CA: bone age advancement; CA, chronological age; CPP, central precocious puberty; E2, estradiol; FSH, follicle stimulating hormone; GLU, fasting glucose; HOMA-IR, homeostasis model assessment of insulin resistance; IGF-1, insulin-like growth factor-1; LH, luteinizing hormone; NC, normal control; P-, peak; PT, premature thelarche.